Replies to post #755999 on NorthWest Biotherapeutics Inc (NWBO)

[manibiotech]

Here ". DCVax works, targeting all tumor-based cancers, is highly scalable, and is extensively protected by patents."
lol Selective amnesia I guess .  Point you never mentioned . You can't make this stuff up unless you are paid to do so . But that's ok if that's what you need to keep lights on. 

[skitahoe]

GGB,

I've asked this question before, even if Keytruda is very effective when used with DCVax-L and it's proven in trials, how does that protect Keytruda if generic forms of it are available.

How does a trial with Keytruda that's successful prevent someone from using DCVax-L with the Keytruda generic.

Having heard that much about benefits with Poly-ICLC I'm still not certain that Keytruda will dominate with DCVax-L, especially if in some cancers Poly-ICLC is shown to work better.

Of course if Merck either has a major equity position in NWBO, or buys the company, it could become its major earner, but it's a very different business than a product they make by the millions of doses.

If it comes down to a buyout, I wouldn't be surprised if many other BP's might get into the bidding. I suppose the same should be true of equity partnerships, Merck isn't the only possibility.

Gary